Drug profile

The FDA adverse-event record for Betamethasone + Clotrimazole + Gentamicin

77 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Betamethasone + Clotrimazole + Gentamicin. See the species affected, top reactions, and outcomes below.

77
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
20
Deafness - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
77
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

BetamethasoneClotrimazoleGentamicin

Administration Routes

Auricular (Otic)UnknownOralHemodialysisTopical

Species Affected

Dog 70
Unknown 7

Most Affected Breeds

Unknown 10
Retriever - Labrador 9
Crossbred Canine/dog 7
Pug 4
Maltese 4
Poodle (unspecified) 3
Terrier - Yorkshire 3
Dog (other) 3
Chihuahua 3
Schnauzer (unspecified) 3

Most Reported Reactions

Deafness 20
Partial deafness 16
Drug administration duration too long 16
Temporary deafness 15
Underdose 6
Application site erythema 6
Application site pain 4
Application site papule 3
Vomiting 3
Overdose 3
Containers, Leaking 2
Incorrect route of drug administration 2

Outcome Breakdown

Outcome Unknown
31 (44.9%)
Recovered/Normal
21 (30.4%)
Recovered with Sequela
10 (14.5%)
Ongoing
7 (10.1%)

Betamethasone + Clotrimazole + Gentamicin Adverse Event Insights

77 reports name Betamethasone + Clotrimazole + Gentamicin; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredients: Betamethasone, Clotrimazole, Gentamicin. Administration routes: Auricular (Otic), Unknown, Oral, Hemodialysis.

By species: Dog (70 reports), Unknown (7 reports). By breed: Unknown (10), Retriever - Labrador (9), Crossbred Canine/dog (7).

Leading clinical signs: Deafness (20), Partial deafness (16), Drug administration duration too long (16), Temporary deafness (15). Outcome, 69 coded reports: Outcome Unknown leads at 44.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.